HUMA / Humacyte Inc. (HUMA) Q2 2023 Earnings Call Transcript

Humacyte develops regenerative human tissue for various medical uses, with upcoming BLAs and interest from the US military. Their core technology, Hum more_horizontal

Humacyte Inc. (NASDAQ:HUMA ) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Dr. Laura Niklason - President & CEO Dal more_horizontal

On May 25, 2023, Heather Prichard, the Chief Operating Officer (COO) of Humacyte Inc ( HUMA , Financial), sold 23,402 shares of the company. This move more_horizontal

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.22 per more_horizontal

Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human acellular vessel product for vascular access in more_horizontal

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 12.50% and 100%, respectively, for the quarter ended December 2022. Do the numbers h more_horizontal

DURHAM, N.C., March 21, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally more_horizontal

Humacyte, Inc. (NASDAQ:HUMA ) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Lauren Marek - Investor Relations Laura Ni more_horizontal